How should I treat a skilled‑nursing‑facility adult resident with mild‑to‑moderate COVID‑19, including appropriate antiviral selection, dosing adjustments for renal impairment, and supportive measures?

Treatment of COVID-19 in Skilled Nursing Facilities

For SNF residents with mild-to-moderate COVID-19, initiate nirmatrelvir-ritonavir (Paxlovid) within 5 days of symptom onset as first-line therapy, or use molnupiravir if nirmatrelvir-ritonavir is contraindicated due to drug interactions or renal impairment. 1, 2

Antiviral Selection Algorithm

First-Line: Nirmatrelvir-Ritonavir (Paxlovid)

• Dosing: 300 mg nirmatrelvir/100 mg ritonavir twice daily for 5 days
• Timing: Must start within 5 days of symptom onset
• Evidence: Reduces all-cause mortality, COVID-19 mortality, hospitalization, and serious adverse events 1
• Renal dosing adjustments:
  • eGFR ≥60: Standard dose (300/100 mg twice daily)
  • eGFR 30-59: Reduced dose (150/100 mg twice daily)
  • eGFR <30 not on dialysis: 150/100 mg once daily 3
  • Intermittent hemodialysis: 150/100 mg once daily (well-tolerated and achieves adequate exposure) 3

Critical Barrier: Drug-Drug Interactions

91% of nursing home residents have potential drug-drug interactions with nirmatrelvir-ritonavir 4. The most common culprits are:

• Atorvastatin (hold during treatment)
• Tamsulosin (hold during treatment)
• Amlodipine (hold during treatment)
• 29% have absolute contraindications requiring alternative therapy 4

Action required: Review medication list immediately upon COVID-19 diagnosis. If contraindications exist or medication adjustments are unsafe, proceed directly to molnupiravir.

Second-Line: Molnupiravir

• Dosing: 800 mg twice daily for 5 days
• Timing: Within 5 days of symptom onset (real-world SNF data shows benefit even within 8 hours) 5
• Advantages in SNF setting:
  • No renal dose adjustment needed 4
  • Zero drug-drug interactions 4
  • Oral capsules easier to administer than IV remdesivir 4
• Evidence: Reduces all-cause mortality and time to recovery 1
• Real-world SNF outcomes: In 107 frail SNF residents (mean age 85.6 years, 77.5% wheelchair-dependent), early molnupiravir resulted in only 0.9% mortality with one deterioration requiring hospitalization 5

Treatment Escalation Planning

Establish treatment escalation plans immediately upon COVID-19 diagnosis because SNF residents can deteriorate rapidly 6. This is non-negotiable.

Immediate Hospital Transfer Criteria

• SpO₂ ≤93% at diagnosis (moderate illness) 5
• Respiratory distress despite positioning and oxygen
• Altered mental status beyond baseline
• Hemodynamic instability

Monitoring Protocol

• Check oxygen saturation at least twice daily for first 5 days
• Assess respiratory status, mental status, and vital signs
• Day 3 is critical: deterioration most likely occurs on day 3 despite antiviral treatment 5

Supportive Measures

For Cough (Distressing)

• Positioning: Avoid lying flat on back 6
• Pharmacologic options (short-term use):
  • Codeine linctus
  • Codeine phosphate tablets
  • Morphine sulfate oral solution 6

For Breathlessness

• Controlled breathing techniques:
  • Positioning (upright, forward-leaning)
  • Pursed-lip breathing
  • Breathing exercises
  • Coordinated breathing training 6

For Fever

• Acetaminophen or NSAIDs as appropriate for comorbidities

What NOT to Use

• Ivermectin: Do not use 1
• Sotrovimab: Do not use (no longer effective against current variants) 1
• Inhaled or oral glucocorticoids: No role in mild-to-moderate community treatment 7
• Immune therapies: No role in mild-to-moderate community treatment 7

Common Pitfalls to Avoid

1. Delayed treatment initiation: The 5-day window is critical. Do not wait for "worsening" to start antivirals—by then, the window may have closed.

2. Missing drug interactions with nirmatrelvir-ritonavir: 61% of SNF residents require medication modifications 4. Review the medication list before prescribing, not after.

3. Ignoring renal function: 29% of SNF residents need dose adjustment for nirmatrelvir-ritonavir 4. Check eGFR before prescribing.

4. Assuming vaccination eliminates need for treatment: In the SNF study, 88.7% were vaccinated and 77.5% had ≥5 doses, yet still required antiviral treatment 5. Vaccination reduces but does not eliminate risk in frail elderly.

5. Underutilizing molnupiravir: Given its safety profile in renal impairment and zero drug interactions, molnupiravir is often the more practical choice in SNF settings despite being labeled "second-line" 4.

Infection Control

• Isolate infected residents (single rooms if possible, cohorting if necessary)
• Standard, contact, and droplet precautions
• PPE for all staff entering room
• Limit movement of infected residents within facility

Vaccination Status

Encourage vaccination in all residents, particularly those unvaccinated or vaccine-hesitant, as it remains the single most effective intervention for reducing severe disease 7. However, suboptimal up-to-date vaccination rates persist in SNFs (2022-2024 data), representing a missed prevention opportunity 8.